Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference19 articles.
1. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma;Moertel;N Engl J Med,1990
2. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20, 898 patients on 18 randomized trials;Sargent;J Clin Oncol,2009
3. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20, 898 patients on 18 randomized trials;Sargent;J Clin Oncol,2005
4. End-points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group;Sargent;J Clin Oncol,2007
5. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy;Kopetz;J Clin Oncol,2009
Cited by 94 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Association between event-free survival and overall survival in early-stage triple-negative breast cancer;Future Oncology;2023-08-21
2. pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients—An Updated Pooled Analysis of Eleven International Randomized Trials;Cancers;2023-06-16
3. Navigating treatment options for sacral spine lymphoma: A medical journey;International Journal of Surgery Case Reports;2023-06
4. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan;Clinical Colorectal Cancer;2023-03
5. Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review;Clinics and Research in Hepatology and Gastroenterology;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3